# Abstracts

**Basic science**
- ix1 NSCLC, locally advanced
- ix9 NSCLC, metastatic

**Biomarkers**
- ix9 Melanoma and other skin tumours

**Breast cancer, early stage**
- ix19 Palliative care

**Breast cancer, locally advanced**
- ix30 Psycho-oncology

**Breast cancer, metastatic**
- ix35 Sarcoma

**CNS tumours**
- ix42 SCLC

**Developmental therapeutics**
- ix46 Supportive care

**Endocrine tumours**
- ix52 Thoracic malignancies, other

**Gastrointestinal tumours, colorectal**
- ix53 Translational research

**Gastrointestinal tumours, non-colorectal**
- ix68 Tumour biology and pathology

**Genitourinary tumours, non-prostate**
- ix86 General interest

**Genitourinary tumours, prostate**
- ix90 Late-breaking abstracts

**Gynaecological cancers**
- ix94 Drug index

**Haematological malignancies**
- ix104 Translational Research index

**Head and neck cancer**
- ix112

**Immunotherapy of cancer**
- ix123

**Melanoma and other skin tumours**
- ix126

**Neuroendocrine tumours**
- ix130

**New diagnostics**
- ix132

**NSCLC, early stage**
- ix134

**NSCLC, locally advanced**
- ix136

**NSCLC, metastatic**
- ix139

**Palliative care**
- ix157

**Psycho-oncology**
- ix161

**SCLC**
- ix169

**Sarcoma**
- ix163

**Supportive care**
- ix170

**Translational malignancies, other**
- ix177

**Translational research**
- ix179

**Tumour biology and pathology**
- ix181

**General interest**
- ix184

**Late-breaking abstracts**
- ix190

**Drug index**
- ix192

**Translational Research index**
- ix194

---

**Note: Abstract suffixes**

- “O” indicates a submitted abstract accepted for Proffered Paper (oral) presentation
- “PD” indicates a submitted abstract accepted for Poster Discussion
- “P” indicates a submitted abstract accepted for Poster Presentation
- “TiP” indicates a submitted abstract accepted for Poster Presentation, Trial in Progress
- ___PR indicates a submitted abstract selected for inclusion in the ESMO Press Programme